We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




MALDI Technology Designed for Mass Spectrometry-Based Molecular Microbial Identification

By LabMedica International staff writers
Posted on 22 Jun 2010
A new matrix-assisted laser desorption/ionization (MALDI) system enables identification, taxonomic, classification, and dereplication of microorganisms such as bacteria, and fungi. More...
Classification and identification of microorganisms is achieved effectively and fast using the new high-throughput MALDI-TOF (time-of-flight) mass spectrometry technology.

Bruker Corp. (Billerica, MA, USA) announced that its MALDI Biotyper workflow for microbial identification in clinical microbiology has been selected by the Austrian Agency for Health and Food Safety (AGES; Vienna) for MALDI-TOF-based analyses of microorganisms.

AGES is responsible for several tasks in regard to public health and food safety for the Austrian government. The organization researches, analyzes, and performs inspections according to the policy guidelines of Austrian Food Laws. The agency requires veterinary inspections and dedicates itself to the prevention and control of infectious diseases in the population. Just recently, scientists of the AGES discovered the source of a listeriosis outbreak in Austria and Germany that caused eight deaths due to contaminated cheese products. In order to provide always state-of-the-art microbiologic analyses AGES is the first organization in Austria using the IVD-CE marked IVD MALDI Biotyper system that is in accordance with the European Union in vitro Diagnostic Directive 98/79/EC.

University Prof. Dr. med. Franz Allerberger, head of the Human Medicine Division, AGES commented, "Microbial analyses based on MALDI-TOF mass spectrometry as a molecular identification tool provide premium information in order to describe and differentiate microorganisms very reliably. With advantages in speed, accuracy, and cost per sample over phenotypic standard tests, the MALDI Biotyper has the potential to become a new clinical standard for microbial identification. In particular, for fastidious microorganisms like anaerobic and nonfermenting bacteria, the superior discrimination power of the MALDI Biotyper has been proven in several publications. In order to substantiate the MALDI Biotyper benefit especially for difficult species in the daily clinical routine, AGES will be the leading organization for quality assurance and standardization for the analysis after Legionella infections. In this context we will also perform a respective round robin test comprising labs from all over the world.”

Dr. Guido Mix, Bruker Daltonics director for microbiology business development, concluded, "The MALDI Biotyper is already a very suitable and reliable tool for daily microbiological routine analysis. Globally more than 100 clinical diagnostic labs, as well as further microbiology departments at industrial and academic sites operate this protein fingerprinting-based approach. We are very pleased to collaborate with an organization like the AGES in order to explore the MALDI Biotyper capabilities beyond current standardized operational species identification procedures, and towards strain typing or clone tracking.”

Applications of the system include clinical routine microbial identification (in the European Union [EU] only--for research use only elsewhere), environmental and pharmaceutical analysis, taxonomical research, food and consumer product processing and quality control, as well as in marine microbiology. The MALDI Biotyper method requires minimal sample preparation efforts and offers low cost per sample.

Related Links:
Bruker
Austrian Agency for Health and Food Safety


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.